Impact News +++ SPARC AI Inc. Announces Closing of First Tranche of Brokered LIFE Financing for $4.34 Million from an... (GlobeNewswire EN) +++ SPARC AI Aktie +3,82%

REGENERON Aktie

>REGENERON Aktienkurs

536.2 EUR +3.5% (TradegateBSX)

Ask: 535.6 EUR / 11 Stück

Bid: 531.7 EUR / 11 Stück

Tagesumsatz: 59 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

REGENERON Aktie über LYNX handeln

Intraday

1 Jahr

>REGENERON Performance

1 Woche: -4,8%

1 Monat: -13,5%

3 Monate: -22,8%

6 Monate: -18,5%

1 Jahr: +20,8%

laufendes Jahr: -21,7%

>REGENERON Aktie

Name:

REGENERON PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US75886F1075 / 881535

Symbol/ Ticker:

RGO (Frankfurt) / REGN (NASDAQ)

Kürzel:

FRA:RGO, ETR:RGO, RGO:GR, NASDAQ:REGN

Index:

S&P500, Nasdaq100

Webseite:

https://www.regeneron.com..

Profil:

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases across eye care, immunology, oncology, cardiovascular health, and inflammation. Its current portfolio in..
>Volltext..

Marktkapitalisierung:

54154.61 Mio. EUR

Unternehmenswert:

48911.77 Mio. EUR

Umsatz:

12830.42 Mio. EUR

EBITDA:

3769.08 Mio. EUR

Nettogewinn:

3804 Mio. EUR

Gewinn je Aktie:

36.58 EUR

Schulden:

2327.25 Mio. EUR

Liquide Mittel:

2554.63 Mio. EUR

Operativer Cashflow:

Bargeldquote:

1.72

Umsatzwachstum:

-0.82%

Gewinnwachstum:

-7.94%

Dividende je Aktie:

3.12 EUR

Dividendenrendite:

0.61%

Dividendenschätzung:

0.62%

Div. Historie:

20.05.26 - 0.808306€
20.02.26 - 0.798906€

>weitere anzeigen...

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 60.648 Euro.

Suchwörter:

REGENERON

Letzte Datenerhebung:

03.06.26

>REGENERON Kennzahlen

Aktien/ Unternehmen:

Aktien: 103.02 Mio. St.

Frei handelbar: 97.94%

Leerverk. Aktien: 2.7%

Rückkaufquote: 3.9%

Mitarbeiter: 15410

Umsatz/Mitarb.: 0.8 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 41.68%

Bewertung:

KGV: 14.33

KGV lG: 12.74

KUV: 4.33

KBV: 1.97

PEG-Ratio: 3.27

EV/EBITDA: 12.98

Rentabilität:

Bruttomarge: 80.93%

Gewinnmarge: 29.65%

Operative Marge: 25.76%

Managementeffizenz:

Gesamtkaprendite: 11.28%

Eigenkaprendite: 14.55%

>REGENERON Peer Group

Gesundheit, Antikörper- Behandlung, Augenmedizin, Medizinprodukte & -technik/ Implantate/ Wundpflege, Allergiebehandlung
>Alle Branchen..

>REGENERON Chart & Kurs - NASDAQ

>REGENERON News

03.06.26 - 18:12	CytomX-Aktie im Aufwind nach erweiterter Forschungskooperation mit Regeneron (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.06.26 - 15:57	CytomX gains as licensing deal with Regeneron expands (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.06.26 - 15:42	CytomX-Aktie legt nach erweiterter Regeneron-Kooperation und Millionenzahlung zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.06.26 - 14:03	CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer (GlobeNewswire EN)
	- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY® and Regeneron's Veloci-Bi® platforms -...

02.06.26 - 16:45	Are Options Traders Betting on a Big Move in Regeneron Stock? (Zacks)
	Investors need to pay close attention to REGN stock based on the movements in the options market lately....

01.06.26 - 18:15	Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised) (Zacks)
	REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies....

01.06.26 - 18:15	Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised) (Zacks)
	Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

28.05.26 - 23:21	Regeneron, Gilead therapies eyed as potential Ebola treatments by WHO (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.05.26 - 22:03	Regeneron′s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak (GlobeNewswire EN)
	Inmazeb® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically for the Orthoebolavirus zairense species, and has been administered to hundreds of patients...

27.05.26 - 13:03	ixlayer Appoints Helmut Osorio as General Manager to Accelerate Direct-to-Patient Growth for Biopharma (PR Newswire)
	Former Regeneron, Pfizer and Purdue Pharma commercial leader brings deep expertise as ixlayer expands its award-winning direct-to-patient platform SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- ixlayer, a cloud-based platform powering end-to-end direct-to-patient (DTP) healthcare, today......

26.05.26 - 14:24	Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink? (Barchart)
	Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

22.05.26 - 14:36	Regeneron Pharmaceuticals′s Genetic Hearing Loss Drug Wins EMA Filing Acceptance (AFX)
	WASHINGTON (dpa-AFX) - Friday, Regeneron Pharmaceuticals, Inc. (REGN) announced that Otarmeni has been accepted by European Medicines Agency for review under Accelerated Assessment the Marketing A......

22.05.26 - 13:03

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss (GlobeNewswire EN)

TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union (EU)....

22.05.26 - 08:18	Regeneron Reports Positive Results For Lynozyfic In AL Amyloidosis Trial (AFX)
	WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) said its Phase 1/2 LINKER-AL2 trial showed encouraging results for Lynozyfic in patients with relapsed or refractory systemic amyloid li......

22.05.26 - 00:42	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN (PR Newswire)
	NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.......

21.05.26 - 01:24	$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today (Benzinga)
	Importance Rank: 1 read more...

20.05.26 - 20:18	Regeneron backed Parabilis Medicines seeks U.S. IPO (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

20.05.26 - 13:06	Regeneron Pharmaceuticals Aktie: Warum die gescheiterte Melanom-Studie jetzt alles verändert (Aktiencheck)
	Toronto (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von BMO Capital Markets: Die Analysten von BMO Capital haben das Kursziel für die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol: RGO, NASDAQ-Symbol: REGN) von 900 auf 730 USD gesenkt, das Rating aber auf "outperform" belassen. [mehr]...

19.05.26 - 22:02	Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B (Zacks)
	REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers....

19.05.26 - 12:24	Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates (PBR)
	Helicons are stabilised, cell-penetrant alpha-helical peptides engineered to interact with intracellular protein targets, including those with flat surfaces unsuitable for traditional small molecule engagement. The partnership will investigate The post Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates appeared first on Pharmaceutical Business review....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Tor läßt all seinem Zorn den Lauf. - Altes Testament: Spruch

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram